USD 9.4 billion
Liquid Biopsy Market Size, Share, Growth Analysis, By Product & Services(Assay Kits, Instruments, and Services), By Circulating Biomarker(Circulating Tumor Cells, Circulating Tumor DNA, Circulating Nucleic Acids Exosome/Microvesicle, Cell-free DNA), By Clinical Application(Early Cancer Screening, Therapy Selection, Treatment Monitoring, and Recurrence Monitoring), By Technology(Multi-Gene Parallel Analysis using NGS, and Single-Gene Analysis using PCR), By Application(Cancer Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer), By Sample Type(Blood Samples, Urine Sample, Saliva Sample, and Others), By End User(Hospitals & Clinics, Diagnostic Centers, Reference Laboratories, Academic & Research Centers), By Region - Industry Forecast 2025-2032
Report ID:
SQMIG35J2060 |
Region:
Global |
Published Date: August, 2024
Pages:
219
|Tables:
61
|Figures:
75
Liquid Biopsy Market Insights
Liquid Biopsy Market size was valued at USD 10.32 Billion in 2023 and is poised to grow from USD 11.48 Billion in 2024 to USD 26.85 Billion by 2032, growing at a CAGR of 11.21% during the forecast period (2025-2032).
Global liquid biopsy market is growing rapidly due to its non-invasive nature and increasing incidence of cancer worldwide. Liquid biopsy offers a non-invasive alternative and offers, traditional histology allows for faster cancer diagnosis, monitoring and personalized therapy. Next generation sequencing (NGS) and polymer chain reaction (PCR) have dramatically increased the sensitivity and specificity of liquid biopsies, driving the Liquid Biopsy market growth. Furthermore, the need for full validation and standardization of urine samples is an important limitation. Despite these challenges, the market is poised for significant growth, driven by ongoing R&D activities and increasing focus on personalized medicine. Some AI and ML algorithms are available that can analyze large data sets from liquid biopsy tests to identify the patterns and biomarkers associated with cancer, enabling identification and accurate and timely treatment.
Market snapshot - 2024–2031
Global Market Size
Largest Segment
Reagents and Kits
Fastest Growth
Reagents and Kits
Growth Rate
13.7% CAGR
Global Liquid Biopsy Market ($ Bn)
Country Share for North America Region (%)
To get more reports on the above market click here to Buy The Report
Liquid Biopsy Market Segmental Analysis
The liquid biopsy market is segmented by Product & Services, Circulating Biomarker, Clinical Application, Technology, Application, Sample Type, End-User and Region. Based on Product & Services, the market is segmented into Assay Kits, Instruments, and services. Based on Circulating Biomarker, the market is segmented into Circulating Tumor Cells, Circulating Nucleic Acids Exosome/Microvesicle, Circulating Tumor DNA, Cell-free DNA, Extracellular Vesicles, and Others. Bases on Clinical Applications, the market is segmented into Early Cancer Screening, Therapy Selection, Treatment Monitoring, and Recurrence Monitoring. Based on Technology, the market is segmented into Multi-Gene Parallel Analysis using NGS, and Single-Gene Analysis using PCR. Based on Application, the market is segmented into Cancer Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, and Others), Non-Cancer Application (Non-Invasive Prenatal Testing, Organ Transplantation, and Infectious Disease Testing), Reproductive Health. Based on Sample Type, the market is segmented into Blood Samples, Urine Sample, Saliva Sample, and Others. Based on End-User the market is segmented into Hospitals & Clinics, Diagnostic Centers, Reference Laboratories, Academic & Research Centers, and Others. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America.
Analysis by Biomarker
The circulating nucleic acids biomarker segment will hold the largest Liquid Biopsy market share of 35.96% in 2023, owing to the widespread applications associated with ctDNA in liquid biopsy. Translational cancer researchers use urine analysis to identify tumor-derived ctDNA. The discovery of Circulating tumor DNA offers new opportunities in the future use of urine biopsy for cancer diagnosis by acting as potential biomarkers. ctDNA has been shown to be an alternative source in cancer patients for molecular profiling of tumor DNA, as opposed to invasive methods. A new approach to early cancer diagnosis and monitoring has been achieved through the detection of recombinant ctDNA from cancer cells.
The exosome/microvesicle segment is expected to grow at the fastest CAGR during the forecast period. Exosomes show significant advantages in liquid biopsy. Exosomes are found in virtually all body fluids, including plasma, cerebrospinal fluid, and urine. They have high stability and are embedded in lipid bilayers. Exosomes are an important component that frequently interacts between cells as cancer progresses and metastasizes. Complex exosome-mediated signalling pathways between cancer cells and the tumor microenvironment serve as a key factor in cancer progression throughout history.
Analysis by Application
Cancer application segment dominated the overall Liquid Biopsy market with 86.26% of revenue share in 2023 owing to growing use of liquid biopsies in cancer diagnosis aided by rising incidence of cancer worldwide. A rapidly emerging precision oncology tool that allows for longer monitoring and less invasive molecular diagnostics for therapeutic purposes. Additionally, in June 2022, Ellipta raised $21 million to develop the MCED trial where MCED-related LEVANTIS-0087A research is going on.
The reproductive health segment is anticipated to follow the fastest CAGR of 12.81% during the forecast period owing to promising R&D in liquid biopsy for treatment of reproductive health. The reproductive health segment is expected to grow well throughout the forecast period. Moreover, alliances and partnerships among reproductive health providers encourage segment expansion. For example, in September 2021, Bionano Genomics partnered with Nuprobe on a reproductive health and oncology liquid biopsy test that allows the detection of mutations that NGS cannot.
Global Liquid Biopsy Market By Biomarker (%)
To get detailed analysis on other segments, Request For Free Sample Report
Liquid Biopsy Market Regional Insights
North America dominated the market with a 50.76% revenue percentage in 2023, driven with the aid of heavy funding and the entry of numerous biotechnology corporations carrying out advanced trials. Despite the outbreak of most cancers, led by the rapid technological improvement and rising government policies. Various companies, including the American Society of Clinical Oncology (ASCO) are working to support the use of liquid biopsies, which are expected to boost revenue in this market over the forecast period.
Asia Pacific in the market is expected to grow at the fastest pace at a CAGR of 13.09% during the forecast period, owing to various factors, such as improving healthcare reforms. According to Global Cancer Statistics, in 2022, there will be 10.5 million new cases of cancer in Asia. Government initiatives such as cervical, & lung cancer screening and improved collaboration between government, research institutes, & industry to distribute & provide these tests for cancer research have increased in the last few years.
Global Liquid Biopsy Market By Geography
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Liquid Biopsy Market Dynamics
Drivers
Technological Advancements
- Next-generation sequencing (NGS) and polymer chain reaction (PCR) technologies have greatly improved the sensitivity and specificity of liquid screening tests, and increased adoption in clinical settings.
Increasing Cancer Prevalence
- The increasing incidence of cancer worldwide is driving the demand for liquid biopsy, which provides a non-invasive, accurate and effective method for early detection, monitoring and treatment of cancer.
Restraints
High Cost
- High costs associated with urine biopsies may limit their widespread use, especially in developing regions with limited healthcare budgets. This high cost may limit the widespread use of urine biopsies, especially when patients and health care providers in developing regions face financial barriers. Furthermore, reimbursement for biopsies is complex and often varies by region and health system. Inconsistent reimbursement models and stringent regulatory requirements can delay the approval and commercialization of urine biopsy tests.
Regulatory Reimbursement Challenges’
- Regulatory reimbursement issues pose a major hindrance to the growth of the liquid biopsy market, as stringent regulations and lack of standardized reimbursement policies can delay approval and marketing of these tests.
Request Free Customization of this report to help us to meet your business objectives.
Liquid Biopsy Market Competitive Landscape
The liquid biopsy market is quite fragmented, with the presence of numerous small and massive players. One notable example is the collaboration among the Guardant Health and AstraZeneca. The partnership to be introduced in 2020, objectives to combine Guardant Health's liquid analytics generation with AstraZeneca's oncology department to increase most cancers treatment and diagnosis. Invincible, actual-time inspection capable, as Essential for knowledgeable scientific choice making.
Top Player’s Company Profiles
- F. Hoffmann-La Roche Ltd (Switzerland)
- Thermo Fisher Scientific Inc. (US)
- Illumina, Inc. (US)
- Guardant Health, Inc. (US)
- Biocept, Inc. (US)
- Sysmex Corporation (Japan)
- Menarini Silicon Biosystems (Italy)
- Natera, Inc. (US)
- Biocartis Group NV (Belgium)
- Personal Genome Diagnostics Inc. (US)
- Bio-Rad Laboratories, Inc. (US)
- OncoCyte Corporation (US)
- Adaptive Biotechnologies Corporation (US)
- Angle plc (United Kingdom)
- Epic Sciences, Inc. (US)
- NEOGENOMICS LABORATORIES (US)
- CellMax Life (US)
- MENARINI-SILICON BIOSYSTEMS (Italy)
- LUNGLIFE AI, INC. (US)
- VORTEX BIOSCIENCES (US)
Recent Developments
- In February 2023, Bio-Rad Laboratories, Inc. announced the launch of its ddPCR liquid biopsy test for colorectal cancer diagnosis and treatment monitoring.
- In January 2023, Guardant Health, Inc. announced a partnership with AstraZeneca to develop liquid biopsy tests for cancer diagnosis and treatment monitoring.
- In August 2022, Natera, Inc. announced the launch of its Signatera liquid biopsy test for early cancer detection and treatment monitoring.
Liquid Biopsy Key Market Trends
Integrating AI and ML Technologies
-
The combination of AI and ML technologies is transforming the liquid biopsy market. AI and ML algorithms are used to analyze complex data from liquid biopsy tests, identifying patterns and biomarkers associated with different cancers. This combination increases the accuracy, predictive power and performance of liquid biopsy tests for detection. It enhances decision making, improves patient outcomes, and improves the accuracy of oncology practice.
Liquid Biopsy Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
According to SkyQuest analysis, liquid biopsy market is poised for significant growth owing to its non-invasive nature, technological advancements and increasing demand for precision medicines. But high cost and regulatory challenges may restrain the market growth. The integration of AI and ML technologies is a key trend, increasing the accuracy and predictive power of liquid biopsy, and driving the market forward. As ongoing R&D activities move forward, the liquid biopsy market is expected to play a key role in early cancer diagnosis, management and personalized medicine, ultimately providing patients with outcomes have improved and changed the landscape of accurate oncology.
| Report Metric | Details |
|---|---|
| Market size value in 2022 | USD 9.28 Billion |
| Market size value in 2031 | USD 24.14 Billion |
| Growth Rate | 11.21% |
| Base year | 2023 |
| Forecast period | 2024–2031 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Liquid Biopsy Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Liquid Biopsy Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Liquid Biopsy Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Liquid Biopsy Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Liquid Biopsy Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Liquid Biopsy Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
